Although people with severe COVID had highest risk, mild cases also upped risks.

A recent review from a prominent scientific source has reignited the debate over masks.

The latest data from the Office for National Statistics suggests that more than 1.2 million people in the U.K. report living with long COVID for 12 months or more.

Vorwort: Der Worst Case ist eingetreten. Weltweit wurde die Pandemie politisch beendet, obwohl sich immer noch viele Menschen neu und erneut infizieren. Während die Zahl der Tests abnimmt, die Dunk…

Eine groß angelegte Studie findet keinen Beleg dafür, dass Masken die Verbreitung von Corona gebremst haben. Doch die Schlüsse, die die Forscher ziehen, sind fragwürdig.

Das BfArM hat in Abstimmung mit dem Bundesministerium für Gesundheit wichtige Informationen zu den Anti-COVID-19 Arzneimitteln Paxlovid® (Nirmatrelvir (PF-07321332) + Ritonavir) und Lagevrio® (Molnupiravir) zusammengestellt.

While there are still far more questions than answers about long COVID-19, researchers are beginning to get a clearer picture of the health and economic consequences of the condition.

Um Langzeitbeschwerden einer Covid-19-Infektion zu lindern, bietet die Techniker ihren Versicherten eine kostenlose Nutzung der Fimo-Health-App.

3 patients in last 2 weeks all with significant short term memory issues including forgetting where they are going while driving. No prior dementia. None brought up COVID infection until asked. All three have been infected within past 4 months when asked. Anyone else seeing this?— John Hess MD (@DrJohnHhess) December 27, 2022

Background: There is limited information on the role of different age groups in propagating SARSCoV2 epidemics driven by the Omicron variants. Methods: We examined the role of individuals in different age groups in propagating the Spring, Summer, and Autumn waves of the Omicron epidemics in France using the previously developed methodology based on the relative risk (RR) statistic that measures the change in the proportion of an age group among all cases admitted to ICU for COVID19 before vs. after the peak of an epidemic wave. Higher value of the RR statistic for a given age group suggests a disproportionate depletion of susceptible individuals in that age group during the ascent of the epidemic (due to increased contact rates and/or susceptibility to infection). Results: For the Spring wave (March 14 through May 15), the highest RR estimate belonged to children aged 10 to 19y (RR=1.92 (95% CI (1.18,3.12)), followed by adults aged 40 to 49y (RR=1.45 (1.09,1.93)) and children aged 0 to 9y (RR=1.31 (0.98,1.74)). For the Summer wave (June 27 through Aug. 21), the highest RR estimate belonged to children aged 0 to 9y (RR=1.61 (1.12,2.3)) followed by children aged 10 to 19y (RR=1.46 (0.72,2.93)) and adults aged 20 to 29y (RR=1.42 (0.91,2.23)). For the Autumn wave (Sep. 18 through Nov. 12), the highest RR estimate belonged to children aged 10 to 19y (RR=1.63 (0.72,3.71)), followed by adults aged 30 to 34y (RR=1.34 (0.8,2.25)) and 20 to 24y (RR=1.20 (0.65,2.21)). Conclusions: Children aged 10 to 19y played the greatest relative role in propagating Omicron epidemics, particularly when schools were open, followed by children aged 0 to 9y and adults aged 20 to 29y, as well as adults aged 30 to 49y. Persons aged over 50y played a more limited role in propagating Omicron infection in the community. Additional efforts are needed to increase vaccination coverage in children aged 10 to 19y, as well as younger children and young adults to mitigate Omicron epidemics in the community. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study did not receive any funding ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes This study is based on aggregate, de-identified, publicly available data that can be accessed through refs. 11-13

Background Long Covid is an emerging chronic illness potentially affecting millions, sometimes preventing the ability to work or participate in normal daily activities. COVID-OUT was an investigator-initiated, multi-site, phase 3, randomized, quadruple-blinded placebo-controlled clinical trial ([NCT04510194][1]). The design simultaneously assessed three oral medications (metformin, ivermectin, fluvoxamine) using two by three parallel treatment factorial assignment to efficiently share placebo controls and assessed Long Covid outcomes for 10 months to understand whether early outpatient treatment of SARS-CoV-2 with metformin, ivermectin, or fluvoxamine prevents Long Covid. Methods: This was a decentralized, remotely delivered trial in the US of 1,125 adults age 30 to 85 with overweight or obesity, fewer than 7 days of symptoms, and enrolled within three days of a documented SARS-CoV-2 infection. Immediate release metformin titrated over 6 days to 1,500mg per day 14 days total; ivermectin 430mcg/kg/day for 3 days; fluvoxamine, 50mg on day one then 50mg twice daily through 14 days. Medical-provider diagnosis of Long Covid, reported by participant by day 300 after randomization was a pre-specified secondary outcome; the primary outcome of the trial was severe Covid by day 14. Result: The median age was 45 years (IQR 37 to 54), 56% female of whom 7% were pregnant. Two percent identified as Native American; 3.7% as Asian; 7.4% as Black/African American; 82.8% as white; and 12.7% as Hispanic/Latino. The median BMI was 29.8 kg/m2 (IQR 27 to 34); 51% had a BMI 30kg/m2. Overall, 8.4% reported having received a diagnosis of Long Covid from a medical provider: 6.3% in the metformin group and 10.6% in the metformin control; 8.0% in the ivermectin group and 8.1% in the ivermectin control; and 10.1% in the fluvoxamine group and 7.5% in the fluvoxamine control. The Hazard Ratio (HR) for Long Covid in the metformin group versus control was 0.58 (95% CI 0.38 to 0.88); 0.99 (95% CI 0.592 to 1.643) in the ivermectin group; and 1.36 in the fluvoxamine group (95% CI 0.785 to 2.385). Conclusions: There was a 42% relative decrease in the incidence of Long Covid in the metformin group compared to its blinded control in a secondary outcome of this randomized phase 3 trial. Trial registration: [NCT04510194][1]; IND 152439 ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial NCT04510194 ### Funding Statement Funding Dr. Bramante was supported by grants (KL2TR002492 and UL1TR002494) from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and by a grant (K23 DK124654) from the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH. Dr. Buse was supported by a grant (UL1TR002489) from NCATS. Dr. Nicklas was supported by a grant (K23HL133604) from the National Heart, Lung, and Blood Institute of the NIH. Dr. Odde was supported by the Institute for Engineering in Medicine, the Medtronic Professorship for Engineering in Medicine, and by grants (U54 CA210190 and P01 CA254849) from the National Cancer Institute of the NIH. Dr. Murray was supported in part by the Medtronic Faculty Fellowship. The fluvoxamine placebo tablets were donated by the Apotex pharmacy. The ivermectin placebo and active tablets were donated by the Edenbridge pharmacy. The trial was funded by the Parsemus Foundation, Rainwater Charitable Foundation, Fast Grants, and the UnitedHealth Group Foundation. The funders had no influence on the design or conduct of the trial and were not involved in data collection or analysis, writing of the manuscript, or decision to submit for publication. The authors assume responsibility for trial fidelity and the accuracy and completeness of the data and analyses. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The IRB of record for this trial is Advarra, as stated in the manuscript. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data produced in the present study are available within 2 weeks of request. All data used to produce the 2-week outcomes paper is already available on covidout.umn.edu [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04510194&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F24%2F2022.12.21.22283753.atom

archived 27 Nov 2022 11:07:34 UTC

Bis heute herrscht die irrige Idee, Long Covid sei die normale Erholungsphase nach schwerer Krankheit. Studien belegen das Gegenteil. Ein Problem ist die babylonische Symptomverwirrung.

I'm concerned as we head into winter that most people are unaware/insufficiently informed of how Covid is transmitted, the dangers it poses or how to protect themselves.Here are some things everyone should know.A basic overview for you, your friends or family members. 🧵/1— Pete 😷 #COVIDisAirborne (@PeteUK7) November 6, 2022

Nach Covid-19 sind bei manchen Menschen wichtige Bewusstseinsfunktionen eingeschränkt

Trotz der Zulassung der an die BA.4/5-Omikron-Varianten angepassten mRNA-Impfstoffe der Firmen Moderna und Biontech/Pfizer sind nach wie vor kaum Daten zu ...

Acta Pharmacologica Sinica - Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies

Researchers in London, Ont. have discovered the secret to diagnose long-COVID — and it's found in blood.

#COVID19 kann das Gehirn auf (mindestens) sechs Arten schädigen. Erstens kann die Immunreaktion auf #SARSCoV2 im Atmungssystem eine Neuroinflammation auslösen, die zu einem Anstieg von Zytokinen, Chemokinen und dem Transport von Immunzellen im Gehirn…#LongCovid #Corona pic.twitter.com/iBM0SHw1Vb— Ralf Wittenbrink (@RWittenbrink) October 8, 2022

The covid-19 pandemic has changed our personalities – a study of more than 7000 US adults found that people are less open to new experiences and less conscientious than before the pandemic

#Brainfog kündigt sich bei mir übrigens mit extremen Problemen mit Präpositionen an. Ich verliere dann mein intuitives Sprachgefühl. Ich habe mal Germanistik studiert, Deutsch unterrichtet ey. Was ein Witz. #NichtGenesen— Mirja (@patatatspeciaal) October 7, 2022

Die Corona-Herbstwelle läuft. Das legen die neuen Infektionszahlen zur Omikron-Variante BA.5 nahe. Aber gibt es womöglich schon einen Subtyp, der die aktuelle Situation weiter verschärft? BQ.1.1 bereitet Experten Sorgen.

Scientists and doctors are still only beginning to understand and classify lingering post-coronavirus symptoms.

The authors used cardiopulmonary exercise testing (CPET) to define unexplained dyspnea in patients with post-acute sequelae of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection (PASC). We assessed participants for criteria to diagnose ...

Prof. Dr. Michael Hallek Nehmen Sie an unserem Long Covid-Symposium teil! Diese Veranstaltung bringt Wissenschaftler, Patienten und Praktizierende aus dem Gesundheitsbereich zusammen, um die neuesten Erkenntnisse in der Long Covid-Forschung und die Auswirkungen auf Gesundheit, Gesellschaft und Wirtschaft zu beleuchten. Täglich verdichten sich die Hinweise, dass eine Infektion und Reinfektionen mit SARS-CoV-2 ein erhöhtes Risiko für chronische Krankheiten und langfristige Schäden darstellt. Zu diesen zählen u.a. Herzinfarkte, Schlaganfälle, Hirnschäden und eine Beeinträchtigung des Immunsystems. Die Auswirkungen auf Familien, Gesellschaft, Arbeitskräfte und die Wirtschaft werden immer gravierender.

Battle over COVID-19 guidance gets lost well before vaccines arrive because of hidden bonding between the mainstream and extremes.

All of this will happen again.